| Document |
Document Title |
|
WO/2003/027060A1 |
It is intended to provide compounds represented by the following general formula (1), which show a higher selectivity for muscarinic receptor in smooth muscle than for muscarinic receptor in heart and have a potent antagonism, salts ther...
|
|
WO/2003/026675A1 |
A method and composition for treating a host infected with flavivirus or pestivirus comprising administering an effective flavivirus or pestivirus treatment amount of a described 4'-modified nucleoside or a pharmaceutically acceptable sa...
|
|
WO/2003/027314A2 |
The invention features linker molecules that have at one terminus a amino-protecting group and at the other terminus a phosphorous activating group, typically phosphoramidite. The linker molecules can be used, for example, to produce ami...
|
|
WO/2003/026589A2 |
A compound, method and composition for treating a host infected with a hepatitis C viral comprising administering an effective hepatitis C treatment amount of a described 4'- disubstituted nucleoside or a pharmaceutically acceptable salt...
|
|
WO/2003/024980A1 |
The invention concerns a method for preparing a triphosphorylated organic compound from a monophosphorylated or diphosphorylated compound in the presence of phosphate ions and using dicyclohexylcarbodiimide (DCC) as condensation activati...
|
|
WO/2003/022859A2 |
The present invention provides a nucleoside comprising a pyrazolopyrimidine base and a process for producing the same. In particular, the processes of the present invention comprises using a halogenated pyrazolopyrimidine base and removi...
|
|
WO/2003/022290A1 |
Preventives&sol remedies for diabetic neuropathy which contain cytidine 5’−diphosphocholine (CDP−choline) as the active ingredient. These preventives&sol remedies for diabetic neuropathy are efficacious against neuropathy mainly ca...
|
|
WO2001087913A9 |
The present invention provides a method of preventing or treating retinal degeneration arising from pathophysiological or physical conditions. The method comprises administering to a patient a pharmaceutical composition comprising a puri...
|
|
WO/2003/022861A1 |
The present invention relates to a method for making an indolopyrrolocarbazole compound of the general formula [I] , where the method includes the step of reacting a bisindolylmaleimide compound with an oxidizing agent in the presence of...
|
|
WO/2003/020984A2 |
The present invention describes methods of detecting a nucleic acid in a sample, based on the use of terminal-phosphate-labeled nucleotides as substrates for nucleic acid polymerases. The methods provided by this invention utilize a nucl...
|
|
WO/2003/020738A1 |
A description is given of compounds of the formula which in the 4'-position has the $i((S)-)configuration and wherein R¿1? is C¿1?-C¿12?alkyl, C¿3?-C¿8?cycloalkyl; or C¿2?-C¿12?alkenyl; R¿2? is hydrogen, optionally substituted CÂ...
|
|
WO/2003/020891A2 |
A method of characterizing a nucleic acid sample is provided that includes the steps of: (a) conducting a DNA polymerase reaction that includes the reaction of a template, a non-hydrolyzable primer, at least one terminal phosphate-labele...
|
|
WO/2003/020739A2 |
Modified LNA units are provided that comprises unique base groups. Desirable nucleobase and nucleosidic base substitutions can mediate universal hybridization when incorporated into nucleic acid strands. The novel LNA compounds may be us...
|
|
WO/2003/020734A2 |
The present invention describes new compositions of matter in the form of labeled nucleoside polyphosphates with four or more phosphates. In addition compositions of nucleoside polyphosphates with four or more phosphates that are substra...
|
|
WO/2003/018030A1 |
The present invention relates to methods of treating viral disease using mutagenic nucleoside analogs.
|
|
WO/2003/018599A1 |
Disclosed are compounds of formula (I), wherein R represents Br, J or R?1¿-SO¿3?, wherein R?1¿ is an unsubstituted or substituted C¿1?-C¿5?-alkyl or an unsubstituted phenyl, X is O or NR'', wherein R'' is a usual protective group fo...
|
|
WO/2003/015516A1 |
Compounds, compositions, and methods are provided for treatment of disorders related to mitochondrial dysfunction. The methods comprise administering to a mammal a composition containing pyrimidine nucleotide precursors in amounts suffic...
|
|
WO/2003/015798A1 |
(I) In the formulae, R1, R2, R3, R4, R5, R6, R7, R8, R9, and A have the same meanings as in the description. A method in which pyradine nucleotide and pyradine nucleoside analogues [2] and [3z] undergo in vivo conversion and are further ...
|
|
WO/2003/016423A1 |
Gelation agents which have biological material constituents which are expected as being biocompatible, can be easily produced on a mass scale, and are capable of readily solidifying a large amount of water or an aqueous solution when use...
|
|
WO/2003/014137A1 |
Disclosed are novel compounds of the Formula I that are A3 adenosine receptor agonists, useful for treating various disease states, including cancer, cardiac ischemia, leukopenia, and neutropennia. Formula (I) wherein: R?1¿ is optionall...
|
|
WO/2003/014296A2 |
Compounds containing a specific saturated or unsaturated branched chain terminal group; a polar leading group; and a long-chain aliphatic, non-cyclic, saturated or unsaturated, substituted or unsubstituted, hydrocarbon group linking them...
|
|
WO/2003/011884A1 |
A process for the preparation of ribavirin on an industrial scale is described which comprises the reaction of glycosylation of 3-substituted triazoles in the presence of a Lewis acid. Said process comprises:a) the reaction of a triazole...
|
|
WO2002060454B1 |
The present invention provides a method of treating edematous retinal disorders. The method comprised administration of a pharmaceutical composition comprising a P2Y receptor agonist to stimulate the removal of pathological extraneous fl...
|
|
WO/2003/011886A1 |
A method for producing a mixed crystal of disodium 5'−guanylate and disodium 5'−inosinate (I&plus G mixed crystal), which comprises adding an aqueous mixed solution of disodium 5'−guanylate and disodium 5'−inosinate and a hydroph...
|
|
WO/2003/012051A2 |
Zebularine has hypomethylating activity, and can be used to inhibit, reverse, and/or reduce DNA methylation $i(in vivo) and $i(in vivo). Methods are provided for treating methylation-linked conditions through the application of 2-pyrimid...
|
|
WO/2003/011883A2 |
A process for the preparation of L-ribavirin on an industrial scale is described which comprises the reaction of glycosylation of 3-substituted triazoles in the presence of a Lewis acid and of a solvent. Said process comprises: a) the re...
|
|
WO/2003/011221A2 |
Novel phosphonate compounds are provided including a phosphonoglyoxylamide ester, an $g(a)-keto phosphonophosphinate ester, a carbonylbisphosphonate analog of a nucleotide, and a diazomethylenebisphosphonate analog of a nucleotide, as we...
|
|
WO/2003/011885A1 |
Nucleotide derivatives of formula (1) are described, wherein: G is a hydrogen atom or an optionally substituted aliphatic, heteroaliphatic, cycloaliphatic, polycycloaliphatic, aromatic or heteroaromatic group or a non natural carbon-link...
|
|
WO/2003/011877A2 |
The present invention provides for the preparation β-adenine nucleosides by coupling an adenine derivative containing an unprotected exocyclic amino group at the C-6 position and a blocked arabinofuranosyl derivative, in the presence of...
|
|
WO/2003/010140A2 |
An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula (I) wherein: A is O, S, NR1, or CR1, wherein R1 is defined herein; represents either a single or a double bond;R2 is selected from: H, halogen, R21...
|
|
WO/2003/010179A1 |
The present invention is an efficient synthetic route to 2',3'-dideoxy-2'3'-didehydro-nucleosides. This process utilizes metal mediated allyl chemistry to achieve coupling of a heterocyclic base, including a purine, pyrimidine, or other ...
|
|
WO/2003/010141A2 |
An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: A is O, S, NR?1¿, or CR?1¿, wherein R?1¿ is defined herein; represents either a single or a double bond;R?2¿ is selected from: H, ha...
|
|
WO/2003/007945A1 |
An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula (I): wherein R?1¿ is selected from: H, haloalkyl, (C¿1-6?)alkyl, (C¿2-6?)alkenyl, (C¿3-7?)cycloalkyl, (C¿2-6?)alkynyl, (C¿5-7?)cycloalkenyl, ...
|
|
WO/2003/008432A1 |
The present invention is directed to methods for the preparation of nucleoside $g(a)-modified nucleoside triphosphates and compounds therefrom.$g(a)
|
|
WO/2003/006460A1 |
L−Ascorbic acid−2−o−maleic acid−&agr −tocopherol diester 1−propanol adduct or its pharmacologically acceptable salt&semi cosmetic components, antioxidants, radical scavengers, antiinflammatory agents and elastase inhibitors...
|
|
WO/2003/006625A2 |
Labelled nucleotides and polynucleotides useful in the sequencing of nucleic acids are described. Methods of preparing photocleavable marker nucleotides and photocleavable marker-polynucleotide conjugates are described. Such photocleavab...
|
|
WO/2003/006475A2 |
The present invention relates to large scale preparation of LNA phosphoramidites using a 2-cyanoethyl-N,N,N',N'-tetra-substituted phosphoramidite and a nucleophilic activator, e.g. 2-cyanoethyl-N,N,N',N'-tetraisopropylphosphoramidite and...
|
|
WO/2003/004510A1 |
The invention relates to a method for the synthesis of biopolymers by gradual breakdown from protected synthesis building blocks carrying two-stage protective groups. The two-stage protective groups are split by means of a first exposure...
|
|
WO/2003/004511A2 |
The invention relates to the use of nucleotide substitutes for increasing the in vivo efficacy of nucleic acid molecules and also for inhibiting inflammation in mammals. More particularly, the present invention relates to the use of 2'6'...
|
|
WO/2003/004603A2 |
2'-O-(2-Methylthioethyl), has been incorporated into oligonucleotides and evaluated for antisense properties in comparison with the known 2'-O-(2-methoxyethyl)2'-O-MOE modification. The 2'-O-MOE modified oligonucleotides exhibit improved...
|
|
WO/2003/002104A2 |
The invention relates to the use of the compounds of formula (I), wherein R represents CN, OH, CH¿3? or H¿2?O, for building up and improving the resistance of the skin. The compounds are particularly suitable for prophylaxis in cases w...
|
|
WO/2003/002587A2 |
The present invention relates to novel phosphoramidate compounds and libraries containing such compounds, and methods for preparing such compounds. Compounds of the invention will be useful in a variety of applications, e.g. as a nucleos...
|
|
WO/2003/002563A1 |
Compounds of formula (I) wherein: W¿I? and W¿2? represent, with the carbon atoms to which they are bound, a phenyl group or a pyridinyl group, and at least one of the groups W¿1? or W¿2? represent a pyridinyl group; R¿1? and R¿2? e...
|
|
WO/2003/002588A1 |
This invention relates to the production of $i(S-adenosyl-L-methionine) by means of a simple, economical and efficient chemical process wherein enrichment of the bioactive $i((S,S)-isomer) is achieved.
|
|
WO/2003/000271A2 |
The invention relates to a new method for producing radio-halogenated compounds having very high specific radioactivity. The method improves the stability of the radio-labeled compound such that its biological and/or chemical activity is...
|
|
WO/2003/000056A1 |
The present invention is directed to a method of altering the amount or composition of synovial fluids secreted from joints in a subject in need of such treatment. The method comprises administering to a subject a pharmaceutical composit...
|
|
WO/2003/000713A1 |
Protide compounds of formula (I) wherein X represents H, F, N¿3?, NH¿2?, -CN, or -OMe; X?l¿ represents 0 or NR?7¿; X?2¿ represents O, NH, NR?6¿ or S, or when X?3¿ is O then X?2¿ is absent; X?3¿ is absent, or when X?1¿ is O then...
|
|
WO/2003/000200A2 |
The present invention includes compounds and compositions of $g(b)-halonucleosides, as well as methods to treat HIV, HBV or abnormal cellular proliferation comprising administering said compounds or compositions.
|
|
WO/2003/000254A1 |
Fused cyclic compounds represented by the following general formula [I] or pharmaceutically acceptable salts thereof and remedies for hepatitis C containing these compounds: [I] wherein each symbol is as defined in the description. Becau...
|
|
WO/2002/102822A1 |
(2S,3S,4R,5R)-2-(5-tert-butyl-[1,3,4]-oxadiazol-2-yl)-5-[6-(
4-chloro-2-fluorophenylamino)-9H-purin-9-yl]-tetrahydrofuran
-3,4-diol in polymorphic form.
|
